Granted Patent
B2
US 11,731,956 · App. 17/891,817 · Granted Aug 22, 2023
Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
Inventors:
Bohan Jin (San Francisco, CA); Qing Dong (San Francisco, CA); Gene Hung (San Francisco, CA); Stephen W. Kaldor (San Francisco, CA)
Assignee:
Alumis Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TY-K2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Claims (4)
1. A compound:
or a pharmaceutically acceptable salt thereof.
2. A compound:
or a pharmaceutically acceptable salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 21, 2023
From: JIN, BOHAN; DONG, QING; HUNG, GENE; KALDOR, STEPHEN W.
To: ESKER THERAPEUTICS, INC.
Reel/Frame 062753/0802 →
CHANGE OF NAME
Recorded Feb 21, 2023
From: ESKER THERAPEUTICS, INC.
To: ALUMIS INC.
Reel/Frame 062813/0382 →
Continuity (10)
Continuation
16938183
Provisional Application
62907354
· Sep 27, 2019
Provisional Application
62893721
· Aug 29, 2019
Provisional Application
62875449
· Jul 17, 2019
Provisional Application
62839459
· Apr 26, 2019
Provisional Application
62756942
· Nov 7, 2018
Provisional Application
62749003
· Oct 22, 2018
Cited By (1)